Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have been given an average rating of "Buy" by the six brokerages that are presently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $23.50.
Several analysts have commented on the stock. Guggenheim reiterated a "buy" rating and issued a $19.00 price target on shares of Maze Therapeutics in a research note on Wednesday, April 2nd. Wedbush assumed coverage on shares of Maze Therapeutics in a research note on Tuesday. They issued an "outperform" rating and a $17.00 price target on the stock.
Read Our Latest Stock Analysis on MAZE
Institutional Trading of Maze Therapeutics
Hedge funds have recently made changes to their positions in the business. New York State Common Retirement Fund purchased a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $25,000. Corebridge Financial Inc. purchased a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $57,000. Rhumbline Advisers purchased a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $80,000. Finally, Deutsche Bank AG purchased a new stake in Maze Therapeutics in the 1st quarter worth about $98,000.
Maze Therapeutics Stock Performance
Maze Therapeutics stock traded down $0.59 during mid-day trading on Tuesday, hitting $15.05. The stock had a trading volume of 127,024 shares, compared to its average volume of 118,689. The company has a 50 day moving average of $11.65. Maze Therapeutics has a one year low of $6.71 and a one year high of $17.00.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.39).
About Maze Therapeutics
(
Get Free ReportWe are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Stories
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
